Richard Malley

USPTO Granted Patents = 27 (Patent Applications = 15)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 23)

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 67(Granted Patents)

Company Filing History:

20 out of 1,036

Children's Medical Center Corporation

Genocea Biosciences, Inc.

patents

4. 1 out of 1

The Chidlren's Medical Center Corporation

patent

5. 1 out of 1,927

University System of Maryland

patents

6. 1 out of 1

Path Vaccine Solutions

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12377140 - Multivalent pneumococcal vaccines (2025-08-05),

2. 12370247 - Multivalent pneumococcal vaccines (2025-07-29),

3. 12370246 - Immunogens and methods for discovery and screening thereof (2025-07-29),

4. 12129283 - Pneumococcal fusion protein vaccines (2024-10-29),

5. 12090198 - Combined vaccine against mycobacterium tuberculosis (2024-09-17),

6. 12083173 - Protein antigens that provide protection against pneumococcal colonization and/or disease (2024-09-10),

7. 12036276 - Multivalent pneumococcal vaccines (2024-07-16),

8. 11981708 - Multiple antigen presenting immunogenic composition, and methods and uses thereof (2024-05-14),

9. 11976097 - Modified biotin-binding protein, fusion proteins thereof and applications (2024-05-07),

10. 11701416 - Multivalent pneumococcal vaccines (2023-07-18),

11. 11612647 - Immunogenic compositions (2023-03-28),

12. 11576958 - Protein antigens that provide protection against pneumococcal colonization and/or disease (2023-02-14),

13. 11560410 - Modified biotin-binding protein, fusion proteins thereof and applications (2023-01-24),

14. 11305001 - Multiple antigen presenting system (MAPS)-basedvaccine, immunogenic composition, and uses thereof (2022-04-19),

15. 11235047 - Immunogens and methods for discovery and screening thereof (2022-02-01),

Title: The Innovative Contributions of Richard Malley in Vaccine Technology

Introduction: Richard Malley, a prominent innovator located in Beverly, MA, has made significant strides in the field of vaccine development. With an impressive portfolio of 24 patents, he has dedicated his work towards the prevention and treatment of infectious diseases, particularly those caused by pneumococcal bacteria and mycobacterium tuberculosis.

Latest Patents: Among his latest patents, Richard Malley has developed groundbreaking technologies for pneumococcal fusion protein vaccines aimed at preventing and treating pneumococcal infections. Additionally, he has designed a combined vaccine against mycobacterium tuberculosis, which employs a Multiple Antigen Presenting System (MAPS) immunogenic composition. This innovative approach integrates an immunogenic polysaccharide that induces a robust immune response, paired with peptide or polypeptide antigens linked via complementary affinity molecules. These MAPS immunogenic compositions are designed to elicit both humoral and cellular immune responses to ensure effective vaccination.

Career Highlights: Throughout his career, Richard Malley has been associated with esteemed organizations such as Children's Medical Center Corporation and Genocea Biosciences, Inc. His contributions in these roles have been pivotal in advancing medical science and improving public health through innovative vaccine research.

Collaborations: Richard has collaborated with notable figures in the research community, including coworkers Yingjie Lu and Fan Zhang. Their collective efforts have contributed to enhancing the efficacy and reach of vaccine technologies, showcasing the power of teamwork in scientific innovation.

Conclusion: Richard Malley's commitment to innovation in vaccine technology has positioned him as a key figure in the fight against infectious diseases. With his ongoing developments, he continues to inspire future generations of scientists and inventors aiming to make a difference in global health.

This text is generated by artificial intelligence and may not be accurate.